160 related articles for article (PubMed ID: 32415472)
21. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
Jackson WC; Silva J; Hartman HE; Dess RT; Kishan AU; Beeler WH; Gharzai LA; Jaworski EM; Mehra R; Hearn JWD; Morgan TM; Salami SS; Cooperberg MR; Mahal BA; Soni PD; Kaffenberger S; Nguyen PL; Desai N; Feng FY; Zumsteg ZS; Spratt DE
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):778-789. PubMed ID: 30959121
[TBL] [Abstract][Full Text] [Related]
22. Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.
Phuong C; Chan JW; Ni L; Wall P; Mohamad O; Wong AC; Hsu IC; Chang AJ
Radiat Oncol; 2022 Jan; 17(1):12. PubMed ID: 35057827
[TBL] [Abstract][Full Text] [Related]
23. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
24. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation.
Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Cambria R; Garibaldi C; Tagaste B; Vavassori A; Cattani F; Alterio D; Gherardi F; Serafini F; Rocco B; Musi G; De Cobelli O; Orecchia R
Urol Oncol; 2011; 29(5):523-32. PubMed ID: 20005749
[TBL] [Abstract][Full Text] [Related]
25. Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.
Cozzi S; Finocchi Ghersi S; Bardoscia L; Najafi M; Blandino G; Alì E; Augugliaro M; Vigo F; Ruggieri MP; Cardano R; Giaccherini L; Iori F; Botti A; Trojani V; Ciammella P; Iotti C
Strahlenther Onkol; 2023 Jun; 199(6):554-564. PubMed ID: 36732443
[TBL] [Abstract][Full Text] [Related]
26. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
Anwar M; Weinberg V; Seymour Z; Hsu IJ; Roach M; Gottschalk AR
Radiat Oncol; 2016 Jan; 11():8. PubMed ID: 26792201
[TBL] [Abstract][Full Text] [Related]
28. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
[TBL] [Abstract][Full Text] [Related]
29. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
[TBL] [Abstract][Full Text] [Related]
30. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
31. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
33. Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes.
Ferrera G; D'Alessandro S; Cuccia F; Serretta V; Trapani G; Savoca G; Mortellaro G; Lo Casto A
J Cancer Res Clin Oncol; 2022 Jan; 148(1):89-95. PubMed ID: 34595542
[TBL] [Abstract][Full Text] [Related]
34. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
[TBL] [Abstract][Full Text] [Related]
35. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
[TBL] [Abstract][Full Text] [Related]
37. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
38. Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).
Jereczek-Fossa BA; Rojas DP; Zerini D; Fodor C; Viola A; Fanetti G; Volpe S; Luraschi R; Bazani A; Rondi E; Cattani F; Vavassori A; Garibaldi C; Alessi S; Pricolo P; Petralia G; Cozzi G; De Cobelli O; Musi G; Orecchia R; Marvaso G; Ciardo D
Br J Radiol; 2019 Feb; 92(1094):20180494. PubMed ID: 30379566
[TBL] [Abstract][Full Text] [Related]
39. Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT.
Guckenberger M; Lawrenz I; Flentje M
Strahlenther Onkol; 2014 Jan; 190(1):48-53. PubMed ID: 24196279
[TBL] [Abstract][Full Text] [Related]
40. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
